The current stock price of INCR is 1.14 USD. In the past month the price decreased by -12.31%. In the past year, price decreased by -29.9%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.98 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 20.02 | 500.60B | ||
| MRK | MERCK & CO. INC. | 12.08 | 264.21B | ||
| PFE | PFIZER INC | 7.82 | 142.31B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.34 | 111.38B | ||
| ZTS | ZOETIS INC | 19.79 | 55.30B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.55 | 22.66B | ||
| VTRS | VIATRIS INC | 5.25 | 14.10B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.31 | 11.12B | ||
| CORT | CORCEPT THERAPEUTICS INC | 94.99 | 8.79B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.74B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.41B |
InterCure Ltd. engages in the provision of business of medical cannabis and biomedicine. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.
INTERCURE LTD
Medinat HaYehudim 85
Herzliya 27604 IL
CEO: Alistair Macdonald
Employees: 320
Phone: 972774605012
InterCure Ltd. engages in the provision of business of medical cannabis and biomedicine. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.
The current stock price of INCR is 1.14 USD. The price decreased by -3.39% in the last trading session.
INCR does not pay a dividend.
INCR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
INTERCURE LTD (INCR) currently has 320 employees.
INTERCURE LTD (INCR) has a market capitalization of 62.34M USD. This makes INCR a Micro Cap stock.
ChartMill assigns a fundamental rating of 3 / 10 to INCR. INCR may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months INCR reported a non-GAAP Earnings per Share(EPS) of -0.46. The EPS decreased by -8.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.62% | ||
| ROE | -14.9% | ||
| Debt/Equity | 0.23 |
For the next year, analysts expect an EPS growth of 1550% and a revenue growth 39.3% for INCR